11 completed, 6 terminated, 2 withdrawn. 13 Phase 2, 12 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 9, Terminated 3, Withdrawn 1 |
| Phase 1 | 12 | Completed 6, Terminated 5, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow obatoclax: new trials by email Literature Review of obatoclax trials Research Report on obatoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer Obatoclax Mesylate, Carboplatine and Etoposide, Carboplatin and Etoposide - Extensive-stage Small Cell Lung Cancer | Phase 3 | Withdrawn | Cephalon | 2012-08-01 | 2012-08-15 | |
| Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma bendamustine hydrochloride, obatoclax mesylate, rituximab - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-10-01 | 2013-06-06 | |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Obatoclax for Systemic Mastocytosis Obatoclax Mesylate - Leukemia, Systemic Mastocytosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2009-06-01 | 2011-11-04 |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma obatoclax mesylate, bortezomib, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 11 | 2008-07-01 | 2015-01-12 |
| A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma Obatoclax Mesylate, Temozolomide - Metastatic Melanoma | Phase 1 / Phase 2 | Terminated | Gemin X | 1 | 2008-06-01 | 2016-07-22 |
| A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Obatoclax, Carboplatin/etoposide - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Gemin X | 218 | 2008-05-01 | 2016-07-21 |
| Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) Obatoclax - AML | Phase 2 | Completed | Gemin X | 18 | 2008-04-01 | 2013-08-26 |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia obatoclax mesylate, fludarabine phosphate, rituximab - B-cell Chronic Lymphocytic Leukemia, Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 28 | 2008-01-01 | 2013-09-30 |
| Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma obatoclax mesylate, bortezomib, laboratory biomarker analysis - Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2007-12-01 | 2015-12-04 |
| Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2007-08-01 | 2015-05-05 |
| Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) Obatoclax mesylate, Rituximab - Lymphoma, Follicular | Phase 2 | Completed | Gemin X | 7 | 2007-03-01 | 2016-07-22 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) Obatoclax mesylate (GX15-070MS) - Myelodysplastic Syndromes | Phase 2 | Completed | Gemin X | 24 | 2006-12-01 | 2013-08-26 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer Obatoclax mesylate 250 ml, Docetaxel - Lung Cancer | Phase 1 / Phase 2 | Completed | Gemin X | 47 | 2006-10-01 | 2016-07-21 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Obatoclax mesylate, Bortezomib - Mantle-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Gemin X | 24 | 2006-10-01 | 2016-07-21 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia Obatoclax mesylate (GX15-070MS) - Myelofibrosis | Phase 2 | Completed | Gemin X | 22 | 2006-07-01 | 2013-08-26 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma Obatoclax mesylate (GX15-070MS) - Hodgkin's Lymphoma | Phase 2 | Completed | Gemin X | 13 | 2006-07-01 | 2012-08-06 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Obatoclax mesylate (GX15-070MS) - Hematological Malignancies | Phase 1 | Completed | Gemin X | 44 | 2005-10-01 | 2014-05-12 |
| A Phase I/II Study of GX15-070MS in Untreated CLL GX15-070MS - Chronic Lymphocytic Leukemia | Phase 1 | Completed | Gemin X | 26 | 2004-09-01 | 2014-05-12 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Small Cell Lung Carcinoma (3) · Leukemia (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Biphenotypic, Acute (1)
Gemin X (11) · National Cancer Institute (NCI) (6) · Cephalon (1) · M.D. Anderson Cancer Center (1)
United States (18) · Canada (7) · Bulgaria (1) · Czechia (1) · Hungary (1) · India (1) · Poland (1) · Romania (1) · Serbia (1) · United Kingdom (1)
Jean Viallet, MD (9) · Mark Berger, MD (2) · Alexander Stewart (1) · Elizabeth Christian (1) · Jennifer Brown (1) · Joseph Tuscano (1) · Lee Krug (1) · Richard Aplenc (1) · Srdan Verstovsek, MD (1)
PMID 18931344, PMID 19088047, PMID 20709666, PMID 21620511, PMID 22383790, PMID 23393050, PMID 24997137, PMID 25052051, PMID 25285531
N01CM62203 (1), N01CM62205 (1), N01CM62208 (1), U01CA062490 (1), U01CA062505 (1), U01CA076576 (1), U01CA097452 (1)